AstraZeneca's Evusheld gets approval in UK to prevent COVID-19
jetcityimage/iStock Editorial via Getty Images


U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved AstraZeneca's (NASDAQ:AZN) antibody cocktail Evusheld for preventing COVID-19.
MHRA said the decision to grant approval was endorsed by the governmentâs independent expert scientific advisory body, the Commission on Human Medicines, after reviewing the evidence.

MHRA added that Evusheld (tixagevimab/cilgavimab) is authorized to be used before being exposed to the risk of COVID-19 infection in order to prevent disease. Recipients should not be currently infected with or had recent known exposure to a person infected with the COVID-19 virus.
The drug regulator added that in a study in adults, Evusheld was found to reduce the risk of developing symptomatic COVID-19 by 77%, with protection from the virus continuing for at least 6 months following a single dose.
Evusheld is currently under review in the EU.